- Trial phase
- Preclinical / Discovery
- Time to market
- Unknown, preclinical discovery stage; likely 5+ years from any potential commercialization, if it advances at all.
- Why 1/10
- EDG-003 is a preclinical discovery-stage program with no clinical trials, no IND filing, no scheduled readout, and no PDUFA date in the next ~12 months. The company's value (~$4.9B market cap) is overwhelmingly driven by EDG-7500 (Phase 2/3 HCM) and the recent $1.55B+ Servier deal, not by this early program.
EDG-003 is too early-stage to move the stock on its own in the next year. Investors should focus on EWTX's real catalysts: the Phase 3 initiation of EDG-7500 in HCM expected Q4 2026 and any milestone payments from the Servier sevasemten sale. EDG-003 is a pipeline filler at the discovery stage, no trading thesis can be built around it.
Price Chart
Executive Summary
EDG-003 is a preclinical discovery program at Edgewise Therapeutics (NASDAQ: EWTX), not a single clinical-stage drug candidate. It explores novel cardiac modulators for undisclosed cardiometabolic indications. The program has already generated one clinical-stage asset, EDG-7500, now in Phase 2 trials for hypertrophic cardiomyopathy, but no specific EDG-003 candidate has entered human trials. Edgewise recently sold its neuromuscular (sevasemten) program to Servier for up to $2.65B ($1.55B upfront), transforming into a cardiovascular-focused company. EDG-003 represents a long-option, early-stage pipeline program with no near-term binary catalysts.
How It Works
EDG-003 is a discovery program within Edgewise that identifies small-molecule drugs designed to modulate cardiac muscle proteins, aiming to treat cardiometabolic diseases (conditions that involve both heart and metabolic dysfunction). The specific drug candidate(s) in this program and their exact targets have not been publicly disclosed.
Trial Status
EDG-003 is a preclinical discovery program exploring novel small-molecule cardiac modulators for undisclosed cardiometabolic diseases. No IND has been filed, and no clinical trials have been initiated. The program has already produced at least one clinical-stage asset (EDG-7500, now in Phase 2 for hypertrophic cardiomyopathy).
The Two-Sided Case
Upcoming Catalysts
- No EDG-003-specific catalysts scheduled. Company catalysts to watch: Phase 3 trial initiation for EDG-7500 in HCM (expected Q4 2026), Phase 2 EDG-15400 HFpEF data, and potential sevasemten milestone payments from Servier upon regulatory milestones.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Edgewise Therapeutics, Inc. 8-K EWTX ·Originating report